Physicians forced to deal with ‘doctor shopping’ patients thanks to new regulations

State-by-state, physicians will find differing standards on when they’re required to check prescription drug monitoring databases before prescribing opioids, even as their professional organizations continue to fight mandatory requirements.

According to the Washington Post, 18 states now require opioid prescribers to check these databases to ensure patients aren’t getting potentially addictive drugs from other doctors. 13 more states have mandatory checks in limited circumstances. Researchers say making physicians check the databases has been proven to cut down on “doctor shopping” and change prescribing habits.

The American College of Physicians and American Medical Association (AMA), however, continue to support only voluntary checks, arguing it places another burden on already overwhelmed physicians.

“We have taken doctors and turned them into clerical staff and typists,” said Steven Stack, MD, past president of the AMA. “We are locked down at a computer, playing the equivalent of a very boring video game on very bad technology.”

For more on the battle between lawmakers and physicians in addressing opioid prescriptions and addiction, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.